Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
The Director, Regulatory Systems and Operations, reporting to our Chief Regulatory Officer, serves as a strategic leader and driver of regulatory infrastructure and execution. This role partners cross-functionally with internal stakeholders to define, implement, and continuously enhance Regulatory Information Management (RIM) systems and databases, ensuring the integrity, accessibility, and scalability of all regulatory information and documentation.
In parallel, this leader plays a critical role within the global regulatory organization as co-lead of the Global Regulatory Subteam, with accountability for the strategic planning, coordination, and execution of regulatory deliverables. The Director ensures alignment of regulatory activities with development timelines and organizational priorities, driving cross-functional collaboration to deliver high-quality submissions on time.
This position works closely with the Regulatory Strategy Leads to proactively shape and advance regulatory plans across the product lifecycle, providing both strategic oversight and operational leadership to enable successful global regulatory outcomes.
Your role
Regulatory Systems
Regulatory Project Management
What You Bring
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
#LI-Hybrid
Salary range $178,400—$267,600 USD

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.
Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.